Search:   [Advanced]

Showing drug card for Quinupristin (DB01369)

Legend: drug field target field enzyme field

for All Approved Biotech Experimental Illicit Nutraceutical Small Molecule Withdrawn drugs

Version	2.5
Creation Date	2007-07-06 20:25:11
Update Date	2009-04-16 16:48:23
Primary Accession Number	DB01369
Secondary Accession Number	Not Available
Name	Quinupristin
Drug Type	Approved Small Molecule
Description	Quinupristin/dalfopristin is a combination of two antibiotics used to treat infections by staphylococci and by vancomycin-resistant Enterococcus faecium. Dalfopristin inhibits the early phase of protein synthesis in the bacterial ribosome and quinupristin inhibits the late phase of protein synthesis. The combination of the two components acts synergistically and is more effective in vitro than each component alone.
Synonyms	Not Available
Brand Names	Not Available
Brand Mixtures	Synercid (Dalfopristin + Quinupristin)
Chemical IUPAC Name	Not Available
Chemical Formula	C87H117N13O19S2
Chemical Structure
CAS Registry Number	120138-50-3
InChI Identifier	InChI=1/C53H67N9O10S.C34H50N4O9S/c1-6-37-50(68)61-23-11-14-38(61)51(69)59(5)40(26-32-16-18-36(19-17-32)58(3)4)52(70)62-28-35(30-73-43-29-60-24-20-33(43)21-25-60)42(64)27-39(62)47(65)57-45(34-12-8-7-9-13-34)53(71)72-31(2)44(48(66)55-37)56-49(67)46-41(63)15-10-22-54-46;1-7-37(8-2)16-17-48(44,45)28-13-15-38-31(28)34(43)47-32(22(3)4)24(6)11-12-29(41)35-14-9-10-23(5)18-25(39)19-26(40)20-30-36-27(21-46-30)33(38)42/h7-10,12-13,15-19,22,31,33,35,37-40,43-45,63H,6,11,14,20-21,23-30H2,1-5H3,(H,55,66)(H,56,67)(H,57,65);9-12,18,21-22,24-25,28,31-32,39H,7-8,13-17,19-20H2,1-6H3,(H,35,41)/b;10-9-,12-11-,23-18-/t31-,35+,37+,38+,39?,40+,43-,44+,45+;24-,25-,28-,31-,32-/m11/s1/f/h55-57H;35H
InChI Key	PPKJUHVNTMYXOD-DXVBPLDJDX
KEGG Drug	D00852
KEGG Compound	C08032
PubChem Compound	11953896
PubChem Substance	7847917
ChEBI ID	Not Available
PharmGKB ID	PA451215
HET ID	SYB
GenBank ID	Not Available
Drug ID Number [DIN]	Not Available
RxList Link	Not Available
PDRhealth Link	Not Available
Wikipedia Link	http://en.wikipedia.org/wiki/Quinupristin
FDA Label	Show PDF (issued on 1999-09-29)
Material Safety Data Sheet (MSDS)	Not Available
Synthesis Reference	Not Available
Average Molecular Weight	1713.0660
Monoisotopic Molecular Weight	1711.8030
State	Solid
Melting Point	Not Available
Experimental Water Solubility	Not Available Source: PhysProp
Predicted Water Solubility	Not Available Calculated using ALOGPS
Experimental LogP/Hydrophobicity	Not Available Source: PhysProp
Predicted LogP	Not Available Calculated using ALOGPS
Experimental LogS	Not Available
Predicted LogS	Not Available Calculated using ALOGPS
Experimental Caco2 Permeability	Not Available
pKa/Isoelectric Point	Not Available
Mass Spectrum	Not Available
MOL File	Show | Download
SDF File	Show | Download
PDB File	Show | Download
2D Structure
3D Structure
Experimental PDB ID	Not Available
Isomeric SMILES	CCN(CC)CCS(=O)(=O)[C@@H]1CCN2[C@H]1C(=O)O[C@H](C(C)C)[C@H](C)\C=C/C(=O)NC\C=C/C(C)=C\[C@@H](O)CC(=O)CC1=NC(=CO1)C2=O.CC[C@@H]1NC(=O)[C@@H](NC(=O)C2=C(O)C=CC=N2)[C@@H](C)OC(=O)[C@@H](NC(=O)[C@@H]2CC(=O)[C@H](CS[C@@H]3C[N@@]4CC[C@H]3CC4)CN2C(=O)[C@H](CC2=CC=C(C=C2)N(C)C)N(C)C(=O)[C@@H]2CCCN2C1=O)C1=CC=CC=C1
Canonical SMILES	CCN(CC)CCS(=O)(=O)C1CCN2C1C(=O)OC(C(C)C)C(C)C=CC(=O)NCC=CC(C)=CC(O)CC(=O)CC1=NC(=CO1)C2=O.CCC1NC(=O)C(NC(=O)C2=C(O)C=CC=N2)C(C)OC(=O)C(NC(=O)C2CC(=O)C(CSC3CN4CCC3CC4)CN2C(=O)C(CC2=CC=C(C=C2)N(C)C)N(C)C(=O)C2CCCN2C1=O)C1=CC=CC=C1
Drug Category	Antibacterial Agents
ATC Codes	Not Available
AHFS Codes	Not Available
Indication	For the treatment of bacterial infections (usually in combination with dalfopristin).
Pharmacology	Quinupristin is a streptogramin antibiotic, derived from pristinamycin I.
Mechanism of Action	Quinupristin inhibits the late phase of protein synthesis in the bacterial ribosome.
Absorption	Not Available
Toxicity	Not Available
Protein Binding	Moderate.
Biotransformation	Quinupristin is converted to two conjugated active major metabolites, one with glutathione and one with cysteine.
Half Life	3.1 hours
Dosage Forms	Not Available
Patient Information	Not Available
Contraindications	Not Available
Interactions	Not Available
Drug Interactions	Drug Interaction Amlodipine This combination presents an increased risk of toxicity Arsenic trioxide This combination presents an increased risk of toxicity Astemizole This combination presents an increased risk of toxicity Atorvastatin This combination presents an increased risk of toxicity Carbamazepine This combination presents an increased risk of toxicity Cerivastatin This combination presents an increased risk of toxicity Cisapride This combination presents an increased risk of toxicity Clarithromycin This combination presents an increased risk of toxicity Cyclosporine Synercid increases the effect of cyclosporine Delavirdine This combination presents an increased risk of toxicity Diazepam This combination presents an increased risk of toxicity Dihydroquinidine barbiturate This combination presents an increased risk of toxicity Diltiazem This combination presents an increased risk of toxicity Disopyramide This combination presents an increased risk of toxicity Docetaxel This combination presents an increased risk of toxicity Dofetilide This combination presents an increased risk of toxicity Droperidol This combination presents an increased risk of toxicity Erythromycin This combination presents an increased risk of toxicity Etoposide This combination presents an increased risk of toxicity Felbamate This combination presents an increased risk of toxicity Felodipine This combination presents an increased risk of toxicity Flecainide This combination presents an increased risk of toxicity Foscarnet This combination presents an increased risk of toxicity Fosphenytoin This combination presents an increased risk of toxicity Gatifloxacin This combination presents an increased risk of toxicity Grepafloxacin This combination presents an increased risk of toxicity Halofantrine This combination presents an increased risk of toxicity Indinavir This combination presents an increased risk of toxicity Isradipine This combination presents an increased risk of toxicity Lercanidipine This combination presents an increased risk of toxicity Levofloxacin This combination presents an increased risk of toxicity Levomethadyl Acetate This combination presents an increased risk of toxicity Lidocaine This combination presents an increased risk of toxicity Losartan This combination presents an increased risk of toxicity Lovastatin This combination presents an increased risk of toxicity Methylprednisolone This combination presents an increased risk of toxicity Midazolam This combination presents an increased risk of toxicity Moexipril This combination presents an increased risk of toxicity Moxifloxacin This combination presents an increased risk of toxicity Nevirapine This combination presents an increased risk of toxicity Nicardipine This combination presents an increased risk of toxicity Nifedipine Synercid increases the effect of ziprasidone Nimodipine This combination presents an increased risk of toxicity Nisoldipine This combination presents an increased risk of toxicity Octreotide This combination presents an increased risk of toxicity Paclitaxel This combination presents an increased risk of toxicity Pentamidine This combination presents an increased risk of toxicity Quetiapine This combination presents an increased risk of toxicity Quinidine This combination presents an increased risk of toxicity Quinidine barbiturate This combination presents an increased risk of toxicity Ritonavir This combination presents an increased risk of toxicity Salmeterol This combination presents an increased risk of toxicity Simvastatin This combination presents an increased risk of toxicity Tacrolimus This combination presents an increased risk of toxicity Tamoxifen This combination presents an increased risk of toxicity Teniposide This combination presents an increased risk of toxicity Terfenadine This combination presents an increased risk of toxicity Tizanidine This combination presents an increased risk of toxicity Venlafaxine This combination presents an increased risk of toxicity Verapamil This combination presents an increased risk of toxicity Vinblastine This combination presents an increased risk of toxicity Vincristine This combination presents an increased risk of toxicity Vindesine This combination presents an increased risk of toxicity Vinorelbine This combination presents an increased risk of toxicity
Food Interactions	Not Available
Pathways	Not Available
General References	Lamb HM, Figgitt DP, Faulds D: Quinupristin/dalfopristin: a review of its use in the management of serious gram-positive infections. Drugs. 1999 Dec;58(6):1061-97. [PubMed ] Paradisi F, Corti G, Messeri D: Antistaphylococcal (MSSA, MRSA, MSSE, MRSE) antibiotics. Med Clin North Am. 2001 Jan;85(1):1-17. [PubMed ] Allington DR, Rivey MP: Quinupristin/dalfopristin: a therapeutic review. Clin Ther. 2001 Jan;23(1):24-44. [PubMed ] Manzella JP: Quinupristin-dalfopristin: a new antibiotic for severe gram-positive infections. Am Fam Physician. 2001 Dec 1;64(11):1863-6. [PubMed ] Wikipedia
Organisms Affected	Enteric bacteria and other eubacteria

This project is supported by Genome Alberta & Genome Canada, a not-for-profit organization that is leading Canada's national genomics strategy with $600 million in funding from the federal government. This project is also supported in part by GenomeQuest, Inc., an enterprise genomic information company serving the life science community.